Abstract Dementia defines wide-ranging symptoms related to a decline in memory or coherent thinking. The focused endeavor of the present study was to develop and assess the efficacy of rivastigmine… Click to show full abstract
Abstract Dementia defines wide-ranging symptoms related to a decline in memory or coherent thinking. The focused endeavor of the present study was to develop and assess the efficacy of rivastigmine hydrogen tartrate (RHT) loaded nanostructured lipid carrier (RHT-NLCs) for the cure of dementia. The rise of dementia cases necessitates a curative therapy which is safe as well as effective. RHT-NLCs were developed by a modified solvent emulsification-diffusion method. Box-Behnken design was used for optimization of the developed formulation. The particle size, polydispersity index, zeta potential and percent entrapment efficiency of the optimized RHT-NLCs formulation was found to be 266 ± 0.94 nm, 0.233, −16.58 mV and 61.82 ± 2.52% respectively. RHT-NLCs displayed 81.23 ± 2.14% drug diffusion in 12 h through goat nasal mucosa and aldicarb assay exhibited increased worm paralysis due to increased concentration of acetylcholine in C. elegans model. Quantitative RT-PCR of RHT-NLCs displayed acetylcholinesterase expressing enzymes (AChE 1 and AChE 2) down-regulation, responsible for the expression of acetylcholinesterase by 4.92 ± 0.06 and 5.42 ± 0.33 respectively. Significant improvement was found in escape latency and transfer latency after treatment with RHT-NLCs in a rat model. Above results point towards the treatment/cure of dementia through RHT-NLCs developed using Compritol 888 ATO, Ryoto Sugar ester and Triacetin.
               
Click one of the above tabs to view related content.